Results 311 to 320 of about 524,302 (394)

Advancing Extracellular Vesicle Research: A Review of Systems Biology and Multiomics Perspectives

PROTEOMICS, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are membrane‐bound vesicles secreted by various cell types into the extracellular space and play a role in intercellular communication. Their molecular cargo varies depending on the cell of origin and its functional state.
Gloria Kemunto, Samaneh Ghadami, Kristen Dellinger   +2 more
wiley   +1 more source

Biomarkers of Probiotic Therapy in Ulcerative Colitis: A Systematic Review of Mechanisms Underlying Remission. [PDF]

Cureus
Farhad ME, Belal I, Baana M, Childs C, Al-Rufayie M.   +4 more
europepmc   +1 more source

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source

DEFB4A/hBD2, a non-invasive serum biomarker for detection of ulcerative colitis. [PDF]

Sci Rep
Chatterjee S, Chakraborty A, Roy S, Roychowdhury D, Karmakar A, Saha A, Dhali GK, Banerjee S, Banerjee A.   +8 more
europepmc   +1 more source

Pharmacokinetic Model Selection for Personalized Infliximab Dosing in IBD

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Infliximab, a monoclonal antibody used for immune‐mediated diseases, shows high interpatient pharmacokinetic variability. Prolonged exposure increases the risk of adverse effects and costs, making dose personalization essential to balance safety, efficacy, and cost‐effectiveness. Population pharmacokinetic models support individualized dosing,
Sahira Chaiben, Peggy Gandia, Thibaut Jamme, Nicolas Congy, Didier Concordet   +4 more
wiley   +1 more source

Recurrent Clostridium difficile Infections in a Patient With Ulcerative Colitis: A Case Report. [PDF]

Cureus
Nadeem O, Imran MS, Siddique N.
europepmc   +1 more source

A Tutorial on the Development of a Physiologically Inspired PKRO Model for Monoclonal Antibodies

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Modeling and simulations are indispensable tools to describe pharmacokinetics (PK) and pharmacodynamics to support monoclonal antibody (mAb) development. The linear PK of mAbs is commonly described by a 2‐compartment PK model, while the nonlinear PK often observed at low doses is described by target mediated drug disposition (TMDD) models ...
Georgi I. Kapitanov, David Flowers, Diana H. Marcantonio, Timothy R. Lezon, Josh F. Apgar, Fei Hua   +5 more
wiley   +1 more source

Genetic and Epigenetic Factors in Ulcerative Colitis: A Narrative Literature Review. [PDF]

Genes (Basel)
Caba L, Florea A, Cianga P, Drug V, Popescu R, Mihai C, Ciobanu CG, Iacob VV, Florea L, Gorduza EV.   +9 more
europepmc   +1 more source

Efficacy and safety of anifrolumab across organ domains of systemic lupus erythematosus: A systematic review and meta‐analysis

Rheumatology &Autoimmunity, EarlyView.
A systematic review and meta‐analysis were conducted to review all clinical trial results of anifrolumab for treating systemic lupus erythematosus. Fourteen studies were included comprising 1322 patients and five studies were meta‐analyzed. It was found that anifrolumab 300 mg IV led to clinical improvement across composite lupus scores, cutaneous ...
Yomna W. Mahmoud, Mohamed Ramadan S., Doaa Radwan G., Mariam S. Abdulhafiz, Yassin M. El‐Shnawy, Alaa Alaa H., Sara Naser Sebie, Maryam A. Elashmawi, Husni Zahi M., Mohammad T. Abuawwad, Mohammad J. Taha, Abdulqadir J. Nashwan   +11 more
wiley   +1 more source

Quercetin alleviates ulcerative colitis via regulating gut microbiota and tryptophan metabolism. [PDF]

mSystems
Xiong M, Kuang W, Liu Z, Tong R, Deng X, Wang N, Wan X, Feng M, Luo Y, Zhang B, Zhang Z, Zheng F.   +11 more
europepmc   +1 more source